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H ow much research does Baptist Health South Florida do?  Baptist Health comprises 11 hospitals and 10 institutes as well as several other departments and centers that conduct 
research.  As of right now, each institute and department tracks their 
own studies and self-reports their information.  As you can see from the 
self-report figures and chart below, we have over 400 retrospective and 
prospective (therapeutic and non-therapeutic) studies taking place with 
over 10,000 participants (5K in the VIRUS registry and 2.5K in the Miami 
Heart Study).  That doesn’t include the studies currently taking place 
with independent  investigators who are not part of a designated center 
or institute conducting research.  
You may be thinking, how do we 
get a handle on it all?  What is the 
source of truth?  One of the ways 
the BHSF research community is 
doing that is by transitioning all 
clinical research to OnCore.  From OnCore 
and the analytics program Insights, 
research leadership easily can run reports 
to see how many studies are open, how 
many participants are enrolled, how 
many are on active treatment, 
and how many are in follow–up.  
We are excited to share more as 
the transition continues! 
Elevating care through discovery.                 July 2021, Vol. 2, Iss. 4 
“Every brilliant 
experiment, like 
every great work of 
art, starts with an 
act of imagination.” 
~Jonah Lehrer~ 
New patients enrolled 
in prospective trials 
during May 2021 
Total patients 
currently participating  
in prospective 
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BITTERSWEET RETIREMENT – ROSE ALLEN, DNP 
A fter 37 years as a nurse at BHSF and 18 years as a member of BHSF IRB, I have retired as of June 25, 2021. I feel very 
fortunate to have had this opportunity to fulfill my amazing career 
first as a Critical Care nurse, then educator, researcher, and nurse 
ethicist. 
I joined the BHSF IRB in 2003 when appointed as BHSF 
Director of Bioethics Program, after working for 18-years in the 
Critical Care Unit at Baptist Hospital. I had very little exposure to 
research prior to joining the IRB, but was welcomed with open arms 
by then chair, Dr. Harold Goldstein. The required CITI training prepared me and allowed me 
to feel more comfortable as a member.  By 2004, I was motivated to conduct my first 
research study on “Advance Directives Use in Acute Care Hospitals”, which was published 
2005 in JONA’s Healthcare Law, Ethics, and Regulations. Subsequently, I conducted other 
research over the years. 
My 18-year IRB membership taught me so much through all the various protocols presented 
on a monthly basis, and the research conferences and workshops offered to all members 
each year. I have also valued the professional expertise of our IRB interdisciplinary members 
of physicians from different specialties, pharmacists, nurse scientists, legal counsel, clergy, 
community members, and IRB management staff.  
Photo by Huper by Joshua Earle on Unsplash  
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Challenges and Opportunities  
 RESEARCH AT BOCA RATON REGIONAL 
HOSPITAL DURING THE PANDEMIC  
W hen I go back to March 2020 and all the uncertainty we faced, the thing 
that stays in my mind is the teamwork, 
collaboration, and support we gave to 
each other.  With so many decisions in 
an unprecedented situation, my main goal 
was to focus on staff and patient safety. On 
the other hand, we had a great opportunity 
to bring novel experimental therapies to our 
patients for the still very much unknown 
COVID-19 disease.  
We held frequent staff meetings and we all 
were engaged in the decision process and 
planning. It was important to be able to 
maintain most of our enrolled patients 
under their treatment regimens, 
especially our cancer patients, evaluate 
what procedures and assessments were 
crucial for patient safety, and coordinate with 
the clinic’s newly established pandemic  
protocols. Our researchers were on board 
with the decision and worked with the 
research nurses and clinical research 
coordinators to make the adjustments 
needed.  Likewise, all our sponsors, except 
for one oncology trial, kept the studies 
ongoing at our site. Back in December 2019 
we had worked with Baptist  Health legal 
and compliance departments to align our 
current monitor credentialing process to 
Baptist Health standards. The final 
guidelines and new polices were 
implemented in January 2020. These 
guidelines allow remote source data 
verification and regulatory review. Remote 
monitoring was one of the key factors the 
sponsors took into consideration when 
deciding to keep sites open.  
Staff safety was a priority, so a rotating 
schedule that included work from home and 
on site, minimized the number of people in 
the office at once and allowed staff to 
maintain appropriate social distancing. The 
regulatory team continued all IRB activities 
including the additional reporting of changes 
in protocols due to the pandemic.  
We faced challenges when some hospital 
procedures were placed on hold, which 
impacted certain study protocol timelines. 
After having approval from IRB, we were 
able to bring the patients back to complete 
their study visits when the hospital re-
opened the services. Incredibly, from March 
to September 2020, we: 
 Enrolled 51 patients in cancer trials 
(11 less than the same period in 2019) 
 Continued with the research treatment 
visits and follow-up visits of enrolled 
patients 
 Performed 30 coronary angiogram CT 
exams (7 more than the same period 
in 2019) 
 Did 8 surgeries with investigational 
devices (9 less than the same period 
in 2019)     
Our physicians were very interested in           
                            (continued on next page) 
Photo by Fusion Medical Animation on Unsplash  
5 
                    (continued from previous page) 
COVID-19 trials.  We engaged with Ohio State University (OSU), Duke University and 
Florida Atlantic University (FAU) to bring some research trials to Boca.  Most of these trials 
were tailored for hospitalized patients, posing a challenge to workflows for the inpatient 
setting, because our current trial portfolio was mostly in the outpatient setting.  Furthermore, 
the research support staff were not able to be at the bedside for consenting and data 
collection, which added research responsibilities to the nursing staff that already had an 
increased burden of care for the COVID-19 patients. Despite these challenges, we opened 
the first COVID-19 treatment trial at our site in July and enrolled 13 patients with the 
full support of the floor nurses and hospital staff.  We were able to provide Convalescent 
Plasma treatment for COVID-19 under individual patient IND to 15 patients and continued 
access through the Mayo Clinic Expanded Access protocol. Then we opened two more 
COVID-19 trials. We would not have been able to open these trials without the collaboration 
of the laboratory personnel and radiation oncology staff because of very specific 
logistics related to laboratory processing and radiation treatment for these trials. 
We have learned to adjust, collaborate, and innovate to ensure we continue to bring the best 
care to our patients and we will be well prepared to take on whatever challenges the future 




T he idea of decentralized clinical trials has been around for several years, but 
they really skyrocketed in the last year with 
the pandemic.  The Clinical Trials 
Transformation Initiative (CTTI) published a 
white paper on recommendations for 
decentralized trials in 2018, which they 
defined as studies that are “executed 
through telemedicine and mobile/local 
healthcare providers, using processes and 
technologies differing from the traditional 
clinical trial model.”  Other names you may 
have heard for decentralized trials include 
mobile, virtual, digital, site-less, and remote.  
Examples of how studies can be 
decentralized include, but aren’t limited to: 
 Remote informed consenting 
 Telehealth visits 
 Wearable health technologies (e.g., 
fitness trackers, smart watches, ECG) 
 Patient-reported outcomes through online 
or phone surveys 
 Home health providers 
 Remote monitoring 









faster screening of adverse events for 
individual trials.  More broadly, decentralized 
trials can improve participant diversity and 
retention by removing certain barriers.  For 
example, converting some visits to virtual 
and providing more options for 
communication increases the chances that a 
participant will complete a visit on time.  
Establishing a long-term strategy to 
incorporate aspects of decentralization on 
the site side will lead to greater trial success. 
—Amy K. Starosciak, Ph.D., Director of 
Outcomes Research, Center for Research 
Image from Medium 
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S everal characteristics make a good randomized, controlled trial (RCT). Blinding, sometimes called masking, is one of these key characteristics. There are three 
primary types of blinding used in RCTs: single, double, and triple. 1) Single blinding 
protects clinical outcomes from observer bias. Simply put, observer bias occurs when the 
treatment administrators “see what they want to see”. By blinding treatment, it protects the 
study’s results from being influenced by an individual’s conscious, or unconscious, 
predisposed ideas of whether a treatment will work or not, or cause a side effect. 2) Double 
blinding, on the other hand, blinds both observer and participants to protect against 
observer bias and something called the Hawthorne effect. The Hawthorne effect is a type 
of bias that occurs when participants of the trial change or improve their behavior only 
because they know they are being observed by others, and not just because of the 
treatment’s effects. 3) Triple blinding blinds observer, participant, and the individuals 
performing the analysis of the final outcomes (e.g., statisticians or whomever completes 
the final analysis of the data) to protect against observer bias, the Hawthorne effect, and 
exposure suspicion bias. Exposure suspicion bias occurs when knowledge of the 
participant’s disease status influences an individual to more likely connect the outcome to 
receiving the treatment. In studies where there is a combination of two treatments, another 
blinding method that is often referred to is double-blinded, double-dummy method which 
blinds both of the treatments simultaneously.  —Daylin Barranco am Darian Daniel, 
Pharmacy Students, Palm Beach Atlantic University and Nova Southeastern University 
BLINDING IN CLINICAL TRIALS 
 













Double Blind, Double Dummy 
AND 
Participant A  
Drug A 
Drug B Placebo 
Placebo 
Bhandar et al. (2010) Canadian Journal of Surgery 
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Explore some of our recent publications! 
New Article Alcove 
Addae JK, Genuir T, Colletta J, Schilling K (2021) Case of second primary breast 
cancer in ectopic breast tissue and review of the literature.  BMJ Case Rep 14
(4):e241361.  Find it here! 
Asburn HJ, Abu Hilal M, Kunzler F, ...De La Cruz L, ...Zinner M, Francis N (2021) 
International Delphi Expert Consensus on Safe Return to Surgical and Endoscopic 
Practice: From the Coronavirus Global Surgical Collaborative. Ann Surg 274(1): 50-
56. Find it here! 
Cortez GM, Monteiro A, …Dabus G, Linfante I, et al. (2021) The use of cangrelor in 
neurovascular interventions: a multicenter experience.  Neuroradiology 63(6): 925-
934.  Find it here!  
Cury RC, Megyeri I, Lindsey T, Macedo R, Batlle J, et al., (2021) Natural language 
processing and machine learning for detection of respiratory illness by chext CT 
imaging and tracking of COVID-19 pandemic in the US.  Radiol Cardiothorac Imaging 
3(1):e200596.  Find it here! 
Ekaireb, Edwards CS, …McDermott MW, Magill ST (2021) Meningioma surgical outcomes and complications in patients 
aged 75 years and older.  J Clin Neurosci 88:88-94.  Find it here! 
Ellingson BM, Sampson J, ...Chowdhary S, ...Vrionis F, et al. (in press) 
Modified RANO, immunotherapy RANO, and standard RANO response 
to convection-enhanced delivery of IL4R-targeted immunotoxin 
MDNA55 in recurrent glioblastoma.  Clin Cancer Res  Find it here! 
LeBlanc KA, Gonzalez A, Dickens E, Olsofka J, Ortiz-Ortiz C, Verdeja J-C, 
Pierce R, Propsective Hernia Group (in press) Robotic-assisted, 
laparoscopic, and open incisional hernia repair: early outcomes from 
the Propsective Hernia Study.  Hernia  Find it here! 
Nassir K, Ziffer JA, Cainzos-Achirica M, Ali SS, Feldman DI, Arias L, 
Saxena A, Feldman T, Cury R, Budoff MJ, Fialkow J (in press) The 
Miami heart Study (MiHeart) at Baptist Health South Florida, A 
prospective study of subclinical cardiovascular disease and emerging 
cardiovascular riskfactors in asymptomatic young and middle-aged 
adults: Rationale and Design.  Am J Pre Cardiol Find it here! 
Rana S, Rosenfeld AB (in press) Impact of errors in spot size and spot 
position in robustly optimized pencil beam scanning proton-based 
stereotactic body radiation therapy (SBRT) lung plans.  J Appl Clin Med 
Phys Find it here! 
Verhoef PA, Kannan S, ...Armaignac DL, et al. (2021) Severe Acute 
Respiratory Syndrome-Associated Coronavirus 2 infection and organ 
dysfunction in the ICU: Opportunities for translational research.  Crit 
Care Explor 3(3):e0374.  Find it here! 
Yagnik GP, Seiler JR, Vargas LA, Saxena A, et al. (2021) Outcomes of 
arthroscopic fixation of unstable distal clavicle fractures: A systematic 
review.  Orthop J Sports Med 9(5):23259671211001773.  Find it here! 
Photo by Henry Be on Unsplash 
Explore more publications from the 
Baptist Health Institutional Repository 
Center for Advanced Analytics 
Center for Research 
Christine E. Lynn Heart & Vascular 
Institute 
Christine E. Lynn Women's Health & 
Wellness Institute 
Eugene M. & Christine E. Lynn Cancer 
Institute 
Marcus Neuroscience Institute 
Miami Cancer Institute 
Miami Cardiac & Vascular Institute 
Miami Neuroscience Institute 
Miami Orthopedics & Sports 
Medicine Institute 
Did we miss your publication?  
Please send it to: library@baptisthealth.net 
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Tuesdays 12:00 to 1:00 pm 
Invite was sent out to Research Operations & 
Regulatory teams. Certificates provided. 
Because of the COVID-19 pandemic, we will be 
doing Zoom™ meetings only until further notice. 
Click here or go to baptisthealth.zoom.us  
Meeting ID: 958 8490 1869 
Password: 861787 
Date Topic 
Tuesday, July 13th Appraisal of Statistical Methods in Research by Emir Veledar, Ph.D. (live) 
Tuesday, August 10th Principles of Good Clinical Practice 
Tuesday, September 14th Participant Safety 
Tuesday, October 12th Preventing Noncompliance 
Tuesday, November 9th Participant Recruitment 
Tuesday, December 14th Study Documentation 
by Pharmacy, Nursing & Clinical Research Organizations 
UPCOMING CONFERENCES 
AONL—July 13-14, 2021, Virtual 
https://www.aonl.org/aonl-virtual-conference 
Global Leadership Summit—August 5-6, 2021, Virtual 
https://globalleadership.org/global-leadership-summit/ 
CCP Annual Meeting—September 13-17, 2021, Virtual 
https://accp1.org/Members/Annual_Meeting/ACCP1/3Annual_Meeting/
Letter_of_Invitation.aspx 
SOCRA—September 24-26, 2021, Virtual 
https://www.socra.org/annual-conference/future-annual-conference-dates/  
ACRP Regulatory Trends & Compliance—September 16, 23, 30, 
2021, Virtual 
https://2021.acrpnet.org/regulatory-trends-compliance 
Onsemble Conference—October 5-8, 2021, Madison, WI  
https://conference.onsemble.net/  
Nursing World Conference—October 18-21, 2021, Virtual 
https//www.magiworld.org/Eventinfo 
MAGI Fall Conference—October 18-28, 2021, Virtual 
https://nursingworldconference.com/  





To serve as a 
research hub for 
elevating care 
through discovery for 
the diverse 
community we serve 
by using a shared 




collaborative intellect.  
 
VISION 
In alignment with the 
strategic goals of 
Baptist Health South 
Florida, and within the 
context of a 
sustainable business 




knowledge with the 
goals of providing 
continued excellence 
in patient care for the 
diverse multicultural 
community of South 
Florida. 
The 2021 Annual Disclosure is now open as of July 1, 2021. It is 
required to complete the Clinical Conflict of Interest (CCOI) Form on an 
annual basis or prior to participating in research at BHSF.  The 
completion of the form is required even if you have nothing to disclose. 
For physicians, it is recommended to first visit CMS Open Payments to 
review the reported data, if any, to ensure a complete disclosure. 
Research personnel will receive an email with the link to the CCOI form 
via PeopleSoft (employees) or REDCap (non-employees). The 
research community has the month of July 2021 to complete the CCOI 
form. As of August 1, 2021, any study that includes a researcher that 
has not completed the 2021 CCOI form, along with the required CITI 
COI and Human Subject training, is non-compliant and will not receive 
compliance confirmation. 
Remember, it is required to complete the CCOI Form within 30 days of 
any changes in financial disclosures.  
Announcement: Research Compliance has a new Research 
Compliance Coordinator, Jacqueline (Jackie) Grass who is providing 
compliance confirmations. Please share your IRBNet studies with 
Jackie and provide her with Read-Only access.  
Do you have any questions or topics you would like 
for us to cover regarding conflicts of interest, 
compliance review, or billing compliance process? If 
so, contact us directly for all Research Compliance 
matters at ResearchCompliance@baptisthealth.net!  
—Heather Osorio, Research Compliance & Billing 
Administrator   
Research Compliance Corner 
To contribute to this newsletter, please contact Dr. Amy Starosciak at amyst@baptisthealth.net or x79546. 
UPCOMING IRB DATES 
BHSF IRB 
Full Board Committee Meeting: Tuesday, July 27th  
Submission Deadline for August Meeting: Monday, July 26th 
MCI IRB 
Full Board Committee Meeting: Monday,  August 2nd 
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